Skye Bioscience Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Skye Bioscience, Inc.a Nevada corporation | ||
| March 21, 2024 | By: | /s/ Punit Dhillon |
|---|---|---|
| Punit Dhillon | ||
| Its: | Chief Executive Officer, Chairman | |
| (Principal Executive Officer) | ||
| March 21, 2024 | By: | /s/ Kaitlyn Arsenault |
| Kaitlyn Arsenault | ||
| Its: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By: | /s/ Punit Dhillon | March 21, 2024 |
|---|---|---|
| Punit Dhillon | ||
| Its: | Chief Executive Officer, Chairman | |
| (Principal Executive Officer) | ||
| By: | /s/ Kaitlyn Arsenault | March 21, 2024 |
| Kaitlyn Arsenault | ||
| Its: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
| By: | /s/ Margaret Dalesandro | March 21, 2024 |
| Margaret Dalesandro | ||
| Its: | Director | |
| By: | /s/ Deborah Charych | March 21, 2024 |
| Deborah Charych | ||
| Its: | Director | |
| By: | /s/ Praveen Tyle | March 21, 2024 |
| Praveen Tyle | ||
| Its: | Director | |
| By: | /s/ Keith Ward | March 21, 2024 |
| Keith Ward | ||
| Its: | Director | |
| By: | /s/ Andrew Schwab | March 21, 2024 |
| Andrew Schwab | ||
| Its: | Director | |
| By: | /s/ Paul Grayson | March 21, 2024 |
| Paul Grayson | ||
| Its: | Director | |
| By: | /s/ Annalisa Jenkins | March 21, 2024 |
| Annalisa Jenkins | ||
| Its: | Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.